Several FLT3 inhibitors have been developed and tested in clinical trials for the treatment of AML, including quizartinib (AC220), sorafenib, or the FDA-approved drugs gilteritinib and midostaurin (PKC-412). This evidence concerns the gene FLT3 and acute myeloid leukemia.